Jiangsu Lianhuan Pharmaceutical Co., Ltd.SSE: 600513

Investor Relations Activity Record Form

May 19, 2026 · Issued by Jiangsu Lianhuan Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · May 19, 2026

On 6ix: 6ix.com/news/investor-relations-activity-record-form-1

Investor Relations Activity Record Form

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Jiangsu Lianhuan Pharmaceutical Co., Ltd. on 6ix

Earlier from Jiangsu Lianhuan Pharmaceutical

Announcement on the Holding Subsidiary Obtaining the Approval Notice for Drug Supplementary ApplicationMay 12
Announcement on Unblinding Results of the Phase III Monotherapy Clinical Trial of the Company's Class 1 New Drug LH-1801 Tablets Combined with MetforminMay 8
Announcement on the Signing of the "Project Entry Contract for the Science and Innovation Center" by with Yangzhou High-tech Industrial Development ZoneApr 28
Announcement on the Execution of Daily Related Party Transactions in 2025 and the Estimated Daily Related Party Transactions in 2026Apr 21
Announcement on Abnormal Fluctuations in Stock TradingApr 9

Later from Jiangsu Lianhuan Pharmaceutical

Announcement on Convening Performance Briefing for 2025 and Q1 2026May 21
Announcement on Resignation of Independent Director Upon Expiration of Term of OfficeMay 22
Announcement on Resolutions of the 2025 Annual General MeetingMay 29
Announcement on Receiving Results of GMP Compliance Inspection Concerning DrugsMay 30
Notice on Convening the 1st Extraordinary General Meeting in 2026Jun 13

All Jiangsu Lianhuan Pharmaceutical news releases

Follow Jiangsu Lianhuan Pharmaceutical into a list and get an email when it puts out news.

Follow Jiangsu Lianhuan Pharmaceutical